Login
Companies $UPB
$2.18 +$0.03 (1.4%) After hours
Upstream Bio, Inc. logo

Upstream Bio, Inc.

upstreambio.com

What Do They Do?

Develops an antibody treatment candidate for patients with severe asthma, chronic rhinosinusitis with nasal polyps, and COPD.

How Do They Make Money?

Maruho reimburses the company for research and development work and drug-supply costs in Japan; revenue is earned as the work progresses.

FY2025 revenue

Who Are Their Customers?

Maruho holds a license and reimburses Upstream Bio for research and development work and drug supply in Japan; Upstream Bio conducts those activities.

Do Revenues Turn Into Profits?

No. It lost $143.4M in FY2025.

Operating income, FY2025
−5619% of revenue
▼ −106% (Loss) vs FY2024 (−$77.8M, −3281%)
Net income, FY2025
−5026% of revenue
▼ −128% (Loss) vs FY2024 (−$62.8M, −2650%)
Free cash flow, FY2025
−4676% of revenue
▼ −124% (Loss) vs FY2024 (−$59.7M, −2518%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −42%
vs $683K in Q3 FY2025
Net income
▼ −22% (Loss)
vs −$33.7M in Q3 FY2025

Who Do They Compete With?

Competes with Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca, and Amgen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support